N Mohseninia, N Zamani-Siahkali, S Harsini… - Seminars in Nuclear …, 2024 - Elsevier
Prostate cancer is the second most common cause of malignancy among men, with bone metastasis being a significant source of morbidity and mortality in advanced cases …
Abstract Piflufolastat F 18 (PYLARIFY®) is an 18 F-labelled diagnostic imaging agent that has been developed by Progenics Pharmaceuticals Inc., a Lantheus company, for positron …
Here, we aimed to develop and validate a fully automated artificial intelligence (AI)-based method for the detection and quantification of suspected prostate tumour/local recurrence …
The main guidelines and recommendations for the implementation of the BRCA1/2 somatic test do not focus on the clinical application of predictive testing on bone metastases, a …
YJL Bodar, WI Luining, B Keizer, D Meijer… - … Oncology: Seminars and …, 2023 - Elsevier
Purpose Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is an emerging staging tool for patients with …
A Friedlaender, O Rager… - healthbook …, 2023 - onco-hema.healthbooktimes.org
Early diagnosis and the detection of distant metastases and recurrences in patients with prostate cancer (PCa) have been notably improved in recent decades through advances in …
The use of PSMA PET has expanded from the detection of recurrent prostate cancer (PCa) to the initial staging of PCa. The use of PSMA PET as a tool for the detection of primary PCa …
NH Hendrikse, RJA van Moorselaar… - VU Research …, 2023 - research.vu.nl
Purpose Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is an emerging staging tool for patients with …
1 LIETUVOS SVEIKATOS MOKSLŲ UNIVERSITETAS MEDICINOS FAKULTETAS MEDICINOS AKADEMIJA RADIOLOGIJOS KLINIKA Deimantė Mėlynytė 6 Page 1 1 LIETUVOS SVEIKATOS …